Laura Dillon
VP Translational Medicine & Bioinformatics,
Incendia Therapeutics
Laura Dillon, Ph.D., is Vice President of Translational Medicine & Bioinformatics at Incendia Therapeutics. She is responsible for biomarker and data science strategy, including the development and application of digital pathology and omics technologies, as well as novel target discovery. Dr. Dillon has over 20 years of experience in industry, academia, and government. Laura was previously the Director of Pathology Data Strategy at AstraZeneca where she focused on developing and implementing machine learning-based methods to extract information from imaging datasets. Laura has a Ph.D. in Bioinformatics and Genomics from the University of Maryland.